Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· January 6, 2026

S&P 500 and Dow Rally to Record Highs as Tech Stocks Surge

View original at nasdaq.com
S&P 500 and Dow Rally to Record Highs as Tech Stocks Surge The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.62%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.99%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.94%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fed policy is clearly restrictive and holding the economy back, and well over 100 basis points of rate cuts are justified this year

    80% confidence

  • It will be possible to cool racks containing Nvidia's new Rubin chips with water at a temperature that does not require a water chiller

    80% confidence

  • The outlook for monetary policy remains in a delicate balance given the conflicting pressures from rising unemployment and still-high inflation

    80% confidence

  • Expects tax cuts and deregulation to lift growth this year

    80% confidence

  • I don't understand what the credit bureaus are doing with their pricing

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com